Opinion|Videos|September 27, 2023
Toxicity Management in Patients With Multiple Myeloma
Experts explain strategies for toxicity management in patients receiving treatment for multiple myeloma, including monitoring risk of CRS.
Advertisement
Episodes in this series
Advertisement
Related to this article
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Advertisement
Advertisement
Trending on CancerNetwork
1
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
2
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
3
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
4
PDS0101/Pembrolizumab Yields 39.3-Month Median OS in HPV16-Positive HNSCC
5